We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
-7.2%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$448M
AUM Growth
+$15.9M
Cap. Flow
+$65.5M
Cap. Flow %
14.64%
Top 10 Hldgs %
71.5%
Holding
29
New
4
Increased
9
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$29.6M
2
BLU
BELLUS Health Inc.
BLU
+$16.2M
3
KURA icon
Kura Oncology
KURA
+$11.2M
4
IMUX icon
Immunic
IMUX
+$10.3M
5
MRUS
Merus
MRUS
+$8.51M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$14.8M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$13.3M
3
ALLK
Allakos
ALLK
+$7.99M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.88M
5
KRON
Kronos Bio
KRON
+$4.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$48M 10.73%
1,816,421
+317,531
+21% +$8.51M
ACRS icon
2
Aclaris Therapeutics
ACRS
$730M
$39.9M 8.91%
2,314,648
-357,698
-13% -$4.88M
BLU
3
DELISTED
BELLUS Health Inc.
BLU
$38.8M 8.66%
5,637,630
+2,513,017
+80% +$16.2M
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$37.3M 8.33%
2,214,961
-1,002,202
-31% -$14.8M
XENE icon
5
Xenon Pharmaceuticals
XENE
$6.32B
$36.8M 8.21%
1,202,613
+112,487
+10% +$3.37M
CYTK icon
6
Cytokinetics
CYTK
$11B
$31.5M 7.03%
854,652
+150,115
+21% +$5.33M
KPTI icon
7
Karyopharm Therapeutics
KPTI
$168M
$26.2M 5.86%
+237,403
New +$29.6M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$26.2M 5.86%
3,500,768
+1,219,453
+53% +$8.49M
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$17.8M 3.99%
5,738,500
+318,604
+6% +$1M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$17.6M 3.93%
951,339
+103,656
+12% +$1.99M
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.3M 3.2%
1,744,570
+497,527
+40% +$4.5M
STSA
12
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$14.1M 3.15%
3,711,286
– –
VTGN icon
13
VistaGen Therapeutics
VTGN
$9.29M
$12.5M 2.8%
336,574
+54,407
+19% +$2.37M
KURA icon
14
Kura Oncology
KURA
$922M
$12.5M 2.79%
+776,514
New +$11.2M
CCCC icon
15
C4 Therapeutics
CCCC
$376M
$11.7M 2.61%
481,094
– –
IMUX icon
16
Immunic
IMUX
$182M
$10.1M 2.25%
+89,301
New +$10.3M
CELC icon
17
Celcuity
CELC
$4.03B
$8.61M 1.92%
920,464
– –
CLDX icon
18
Celldex Therapeutics
CLDX
$2.77B
$8.21M 1.83%
+241,199
New +$7.71M
PTGX icon
19
Protagonist Therapeutics
PTGX
$8.75B
$7.86M 1.76%
331,886
-473,687
-59% -$13.3M
TNYA icon
20
Tenaya Therapeutics
TNYA
$168M
$6.05M 1.35%
513,930
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.61M 1.03%
312,553
– –
GNCA
22
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.85M 0.86%
3,079,756
– –
IVA
23
Inventiva
IVA
$1.05B
$2.99M 0.67%
262,658
– –
DYN icon
24
Dyne Therapeutics
DYN
$4.04B
$2.94M 0.66%
305,125
– –
PMVP icon
25
PMV Pharmaceuticals
PMVP
$66.1M
$2.6M 0.58%
125,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Commodore Capital held 29 positions worth $448M, up 3.7% from $432M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Commodore Capital deployed $65.5M of net new capital in Q1 2022, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Karyopharm Therapeutics: 237,403 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $14.8M trimmed.

  • Commodore Capital's largest Q1 2022 buy was Karyopharm Therapeutics: 237,403 shares worth $26.2M.
  • Commodore Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $16.2M increase.
  • Commodore Capital's biggest Q1 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $14.8M.
  • Commodore Capital fully exited Allakos in Q1 2022, selling an estimated $7.99M.
  • Commodore Capital's ten largest holdings make up 72% of its $448M portfolio in Q1 2022.
  • Commodore Capital opened 4 new positions and closed 2 in Q1 2022.
  • Commodore Capital's portfolio value rose 3.7% quarter-over-quarter to $448M.

Based on Commodore Capital's 13F filing for Q1 2022, filed 16 May 2022.